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Abstract
Vitamin D has many and profound effects on the immune system. Vitamin D 
deficiency is known to be related to the development of autoimmune diseases. In 
particular, vitamin D deficiency is related to the development and the severity of 
rheumatoid arthritis (RA). RA develops in patients with vitamin D deficiency, and 
the activity of the disease is related to vitamin D deficiency. Vitamin D deficiency 
is also related to the development of systemic lupus erythematosus (SLE). SLE 
develops in patients with vitamin D deficiency, and the activity of the disease is also 
greater in patients with vitamin D deficiency. Vitamin D deficiency is also related to 
the development and the severity of multiple sclerosis. Vitamin D should be admin-
istered to patients with multiple sclerosis, and this seems to mitigate the symptoms 
of the disease and to prevent disease progression. Vitamin D deficiency is also 
observed in patients with inflammatory bowel disease and may be related to disease 
severity. Low vitamin D levels have also been observed in patients with autoimmune 
Hashimoto’s thyroiditis. Low vitamin D levels have been observed in patients with 
systemic sclerosis, especially in the diffuse form of the disease. Optimal vitamin 
D levels appear to be required for normal immune function and for the prevention 
and treatment of autoimmune diseases.
Keywords: vitamin D, autoimmunity, rheumatoid arthritis, systemic lupus 
erythematosus, multiple sclerosis, inflammatory bowel disease, autoimmune 
Hashimoto’s thyroiditis
1. Introduction
Vitamin D is a secosteroid hormone, which is known to be related to the regu-
lation of the musculoskeletal system. It affects calcium and phosphate metabo-
lism and is related to bone health. Recently, the extraskeletal effects of vitamin 
D are under intense research and have attracted the interest of the scientific 
community [1–6]. In particular, the relationship of vitamin D with the immune 
system is in the focus of scientific evaluation [7–9]. In the chapter herein, the 
effects of vitamin D on the immune system will be discussed, and the relation-
ship of vitamin D deficiency with the development of autoimmune diseases will 
be reviewed.
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2. Vitamin D and the immune system
The classic function of vitamin D is to enhance intestinal absorption of calcium 
by regulating several calcium transport proteins in the small intestine [4]. However, 
various cells express the vitamin D receptor (VDR) and the vitamin D activating 
enzyme 1-α-hydroxylase. Various cells of the immune system also express the VDR 
and harbor 1-α-hydroxylase [10, 11]. Thus, cells of the immune system respond 
to vitamin D and also activate vitamin D in a paracrine or autocrine fashion. The 
extra-renal 1-α-hydroxylase is not upregulated by PTH, and thus, production of 
1,25(OH)2D3 is dependent on concentrations of the substrate 25(OH)D3, and it 
may be regulated by inflammatory signals, such as lipopolysaccharide and cyto-
kines [12, 13]. Cells of the immune system, which express the VDR and harbor 
1-α-hydroxylase, are macrophages, T cells, dendritic cells, monocytes, and B cells 
(Figure 1) [9]. Vitamin D is involved in the regulation of the innate immunity as it 
enhances the defense system of the organism against microbes and other pathogenic 
organisms, and it modulates the adaptive immune system through direct effects on 
T-cell activation and on the phenotype and function of antigen-presenting cells, 
particularly dendritic cells.
2.1 Vitamin D and the innate immune system
The innate immune system is a first line of defense against infection. Vitamin 
D is a regulator of the innate immune system [1, 14]. The first data on the effect of 
vitamin D on the innate immune system have been generated on the treatment of 
diseases caused by mycobacteria, such as tuberculosis and leprosy [15–18]. Vitamin 
D has been used as a treatment of infections for more than 150 years. In 1849, 
Williams reported favorable results with the use of cod-liver-oil, an excellent source 
of vitamin D, in the treatment of patients with tuberculosis [19]. Fifty years later, 
Niels Finsen received the third Nobel Prize in Medicine for his description of using 
UV light, an effective method to increase vitamin D status, to treat lupus vulgaris, a 
cutaneous form of tuberculosis [20, 21]. Alfred Windaus contributed to the discov-
ery of the chemical structure of vitamin D2 and vitamin D3 found in cod-liver-oil and 
received the Nobel prize [22–24]. Thereafter, several groups used vitamin D2 and D3 
as a treatment for tuberculosis [22, 25]. Rook et al. [26] demonstrated in the 1980s 
that 1,25(OH)2D3 inhibited the proliferation of Mycobacterium tuberculosis in culture. 
Vitamin D enhances the production of defensin β2 and cathelicidin in response to 
infection by macrophages, monocytes, and keratinocytes [12]. Humans have only 
Figure 1. 
Cells of the immune system regulated in part by vitamin D.
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one cathelicidin, which is cleaved to form LL-37 [27]. Cells of the immune system 
including neutrophils and macrophages and cells lining epithelial surfaces that are 
constantly exposed to potential pathogens such as the skin, the respiratory, and the 
gastrointestinal tract produce cathelicidin [28–30]. Cathelicidin has broad antimi-
crobial activity against Gram-positive and Gram-negative bacteria, as well as certain 
viruses and fungi [31]. The killing mechanism of cathelicidin involves bacterial lysis 
by destabilizing cell membrane [32]. Treatment with 1,25(OH)2D3 upregulates cathe-
licidin mRNA in several cell lines. Thus, it appears that 1,25(OH)2D3 upregulates 
antimicrobial peptide production, primarily cathelicidin, on a variety of different 
cells [33]. Studies indicate that 25(OH)D3, the major circulating form of vitamin D 
to determine vitamin D status, is important for local production of 1,25(OH)2D3 to 
upregulate cathelicidin production in the skin and macrophages. Exposing human 
monocytes to pathogens increases the expression of both 1,25(OH)2D3 and VDR, 
thus increasing both the local production of 1,25(OH)2D3 and the ability of the cell 
to respond to it [12]. Since keratinocytes also possess 25-α-hydroxylase, UV light 
may directly stimulate cathelicidin production by providing the substrate 25(OH)
D3 directly from vitamin D3 produced within the skin [34, 35]. Macrophages also 
respond to vitamin D increasing their antimicrobial activity, however, heteroge-
neously [36, 37]. Macrophages formed after interleukin-15 stimulus respond to 
vitamin D increasing their antimicrobial activity, whereas macrophages formed after 
stimulation by interleukin-10 respond to vitamin D stimulus weakly.
Data regarding other infections also exist. Thus, children with low vitamin 
D status may be more prone to urinary tract infections due to low production of 
cathelicidin and defensin β2 [38, 39]. Also, adults with asthma may be less prone to 
infection after treatment with vitamin D due to increased production of cathelidicin 
and modulation of inflammatory cytokines [40, 41]. Low levels of vitamin D may 
be related to chronic obstructive pulmonary disease severity [42]. Vitamin D may 
increase resistance to HIV infection. Low levels of vitamin D have been associated 
with disease progression and mortality [43]. The ability of the immune cells to 
hydroxylate 25(OH)D3 locally suggests that in patients with infections, it may be 
better to administer 25(OH)D3 rather than hydroxylated metabolites to allow for 
local production and the feedback system to function.
2.2 Vitamin D and autoimmunity
The natural history of autoimmunity remains largely unknown. However, the 
theory is that both genetic susceptibility and environmental factors play a role in 
the development of clinical autoimmune disease. Vitamin D has known immuno-
modulatory effects on a wide range of immune cells, including T and dendritic cells 
[44, 45]. Each of these immune cells expresses VDR and produces the enzymes 
1-α-hydroxylase and 24-hydroxylase and is therefore capable of locally producing 
active 1,25(OH)2D3 [46–49]. Activation of CD4+ T cells results in a significant 
increase in VDR expression enabling regulation of many genes responsive to 
1,25(OH)2D3 [50]. 1,25(OH)2D3 suppresses T-cell receptor induced T cell prolifera-
tion and changes their cytokine expression. The overall shift is away from T helper 
Th1 phenotype toward a more tolerogenic Th2 response [51–53]. Vitamin D appears 
to directly inhibit Th1 cells and may additionally modulate a skewing toward a Th2 
response [54]. Th17 cells are a subset of CD4+ T cells involved in organ-specific 
autoimmunity playing a role in maintaining inflammation, which can lead to tissue 
damage. 1,25(OH)2D3 suppresses autoimmunity and tissue destruction by inhibit-
ing the Th17 response at several levels [55, 56]. Altogether, the evidence suggests 
an important role for vitamin D in influencing T-cell responses and in tempering 
inflammation and tissue damage.
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Vitamin D appears to have a direct effect on B cells and inhibits immunoglobulin 
production [57]. Additionally, differentiation of B cells is interrupted when exposed 
to 1,25(OH)2D3. 1,25(OH)2D3 also has effects on dendritic cells. Dendritic cells have 
important functions in maintaining both protective immunity and self-tolerance 
[58, 59]. Physiologic levels of 1,25(OH)2D3 inhibit maturation of dendritic cells and 
maintain an immature and tolerogenic phenotype with inhibition of activation 
markers such as MHC class II, CD40, and others and upregulation of inhibitory 
molecules [60, 61]. Thus, it appears that the maturational state of dendritic cells can 
be modulated by 1,25(OH)2D3, making it possible that the vitamin D status of an 
individual is likely to have important immunologic consequences.
3. Vitamin D and autoimmune diseases
There are several animal models of autoimmunity, in which disease could either 
be prevented or ameliorated with the administration of either 1,25(OH)2D3 or one 
of its analogues. These animal models are models of autoimmune encephalomy-
elitis, collagen-induced arthritis, type 1 diabetes mellitus, inflammatory bowel 
disease, autoimmune uveitis, and lupus [44, 56, 62–76]. These studies show that 
treatment with active vitamin D is effective in modulating immune function and 
ameliorating autoimmune disease. Vitamin D deficiency is a risk factor for the 
development of some autoimmune diseases, such as rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE), diabetes mellitus type 1, multiples sclero-
sis, inflammatory bowel disease, and Hashimoto’s thyroiditis [49, 69, 74, 77–85] 
(Figure 2). Additionally, vitamin D deficiency has been observed in patients with 
systemic sclerosis [86].
3.1 Vitamin D deficiency and rheumatoid arthritis
A meta-analysis showed that low vitamin D intake is associated with the 
development of RA [87]. Thereafter, several studies performed in various areas 
all over the world showed that vitamin D deficiency is observed in patients with 
RA and that vitamin D deficiency is associated with disease activity [78, 82, 83, 
88–97]. A meta-analysis of the good quality studies performed regarding the 
association between vitamin D deficiency and RA showed that vitamin D defi-
ciency is observed in RA patients significantly more than in a control group and 
that vitamin D levels are inversely correlated with disease activity, meaning that 
low vitamin D levels are associated with high-disease activity [98]. Moreover, an 
Figure 2. 
Autoimmune diseases related to vitamin D deficiency.
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association has been shown between VDR polymorphism and RA. Specifically, 
the Fokl F allele of the VDR may be a risk factor for the development of RA [99]. 
Further studies are needed to unravel the exact association between vitamin D 
deficiency and RA and to determine the best method of vitamin D supplementa-
tion and whether it may be used for the prevention of RA or for the best manage-
ment of the disease [77, 100]. In addition, it has been proposed that vitamin D may 
contribute to the management of pain in RA and may be used along with TNF-α 
inhibitors in RA treatment [77, 101].
3.2 Vitamin D deficiency and systemic lupus erythematosus
In SLE, the inflammatory milieu drives the development of T cells into proin-
flammatory pathways, defective function of Tregs, and survival and activation 
of B cells, which produce autoantibodies [78, 81]. Patients with systemic lupus 
erythematosus have lower 25(OH)D3 levels compared to controls, suggesting that 
vitamin D deficiency may be a risk factor for SLE [81, 84, 102–107]. The major-
ity of studies have also found higher SLE disease activity associated with lower 
levels of 25(OH)D3 [84, 103]. As patients with SLE have often photosensitivity 
and are advised to avoid direct sun exposure, detecting vitamin D deficiency and 
replacing 25(OH)D3 with oral supplementation is critical and may impact disease 
activity [108].
3.3 Vitamin D deficiency and type 1 diabetes mellitus
Type 1 diabetes mellitus is one of the most prevalent chronic diseases with 
onset in childhood and is the result of immune-mediated destruction of pancreatic 
insulin producing β cells. There appears to be a geographic variation in incidence 
following a gradient in latitude, which is the inverse of the global distribution of 
ultraviolet B irradiation, critical for the production of vitamin D within the skin 
[109]. Studies have shown higher incidence of vitamin D deficiency in patients with 
type 1 diabetes [110–113]. One environmental factor thought to be protective against 
the development of type 1 diabetes mellitus is early supplementation with vitamin D 
[114]. A number of large case control studies showed that the risk of type 1 diabetes 
mellitus was significantly reduced in infants who were supplemented with vitamin 
D compared to those who were not supplemented [115–117]. Additionally, a lower 
incidence of type 1 diabetes was observed in infants born to mothers who were 
administered cod liver oil during pregnancy [118]. A birth cohort study in Finland, 
now more than 50 years ago, evaluated the effects of vitamin D supplementation 
on rickets and the development of type 1 diabetes mellitus [85]. All women due to 
give birth in 1966 were enrolled. There was an 80% reduction in the risk for type 1 
diabetes mellitus in children having received >2000 IU vitamin D/day compared 
to those receiving less or not receiving supplementation with vitamin D. Evidence 
from both human and animal studies shows that vitamin D may be protective as far 
as the development of type 1 diabetes mellitus is concerned [68, 71, 76]. Thus, the 
administration of vitamin D may prevent diabetes mellitus type 1; however, once the 
destruction of pancreatic beta cells has taken place, it will not act therapeutically to 
reverse diabetes mellitus type 1.
3.4 Vitamin D deficiency and multiple sclerosis
Multiple sclerosis is characterized by inflammation, demyelination, axonal or 
neuronal loss, and astrocytic gliosis in the central nervous system, which can result 
in disability. Epidemiological studies have suggested that vitamin D insufficiency 
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may contribute to the risk of multiple sclerosis [62, 63, 75, 119, 120]. Moreover, 
several genetic studies in multiple sclerosis patients have shown that diverse abnor-
malities in vitamin D metabolism are related to the risk of the disease. It appears 
that vitamin D deficiency may interact with genetic and environmental protective 
and risk factors, such as the allele HLA BRB1*1501, infections, obesity, smok-
ing, and sexual hormones and may modulate the risk of the disease [63, 74, 80]. 
Thus, vitamin D deficiency may be a risk modulating factor for the development 
of multiple sclerosis. Vitamin D acts as an immunomodulatory factor affecting 
T and B lymphocytes, and it may exert neuroprotector and neurotrophic actions 
within the central nervous system. Several studies have shown that vitamin D 
supplementation exerts multiple beneficial immunomodulatory effects in multiple 
sclerosis [121–124]. On the contrary, a Cochrane review states that there appears to 
be no benefit from vitamin D supplementation in patients with multiple sclerosis; 
however, the level of evidence is very low [125]. Nevertheless, it should be noted 
that robust statistical models used in association studies have already predicted 
a favorable vitamin D effect reducing relapses by 50–70% [121]. There is little 
doubt that vitamin D exerts a beneficial action on multiple sclerosis, the inflam-
matory component in particular, less so the degenerative. Until more information 
becomes available, vitamin D supplementation of multiple sclerosis patients, using 
a moderate physiological dose essentially correcting their vitamin insufficiency, is 
recommended.
3.5 Vitamin D and inflammatory bowel disease
Vitamin D deficiency has been observed in patients with inflammatory bowel 
disease, Crohn’s disease, and ulcerative colitis [126]. It was found to be related 
to disease activity in Crohn’s disease and ulcerative colitis. Vitamin D supports 
the integrity of the intestinal barrier and is related to microbiota homeostasis in 
this cohort of patients [127, 128]. Thus, vitamin D may contribute to the preven-
tion of inflammatory bowel disease by supporting the integrity of the intestinal 
barrier, contributing to bacterial homeostasis and ameliorating disease progres-
sion via anti-inflammatory action. Vitamin D deficiency in inflammatory bowel 
disease is aggravated by decreased absorption of the vitamin via the gastrointes-
tinal tract [128].
3.6 Vitamin D deficiency and autoimmune Hashimoto’s thyroiditis
Studies have observed an association between autoimmune Hashimoto’s thyroid-
itis and low vitamin D levels [79, 129]. These studies have not observed low vitamin 
D levels in patients with Graves’ disease. A meta-analysis of 26 observational 
studies confirmed an association between vitamin D deficiency and autoimmune 
Hashimoto’s thyroiditis [130]. The aforementioned meta-analysis found that 
although there was heterogeneity between the results of the various studies per-
formed all over the globe, studies had similar results in populations from different 
countries and also in populations in different age ranges, in particular pediatric and 
adult populations.
3.7 Vitamin D deficiency and systemic sclerosis
Systemic sclerosis is a chronic, inflammatory, fibrotic disorder thought to be 
related to autoimmune etiology. Vitamin D deficiency has been observed in patients 
with systemic sclerosis [86, 131], especially in patients with the diffuse type of the 
disease [131].
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4. Optimal levels of 25(OH)D3
The molecule used to assess vitamin D sufficiency in a population is 25(OH)D3 
[9]. It appears that vitamin D has physiologic effects beyond those related to bone 
physiology and mineral homeostasis. It may be that the alarming prevalence of 
vitamin D deficiency observed all over the globe may be contributing to the devel-
opment of autoimmune diseases. Based on bone-related biomarkers such as intact 
parathyroid hormone, calcium absorption, and bone mineral density, maintaining a 
25(OH)D3 level of at least 32 ng/ml appears sufficient.
5. Conclusions
It appears that vitamin D is a potent immunomodulator. It has multiple and 
diverse effects on the immune system. In particular, it potentiates the innate 
immune response enhancing the production of cathelicidin from human mac-
rophages, monocytes, and keratinocytes, thus enhancing and potentiating the 
immune response against external pathogens. It affects the adaptive immune 
response shifting the phenotype of the adaptive immune response toward a more 
tolerogenic phenotype. Vitamin D deficiency is related to various autoimmune 
disorders. Vitamin D deficiency appears to be related to the development of RA and 
correlates with disease severity. Vitamin D deficiency is observed in patients with 
SLE. It was found to be related to disease severity and activity in some but not all 
studies. Vitamin D deficiency is observed in patients with multiple sclerosis, and 
vitamin D administration may ameliorate disease severity. Vitamin D deficiency 
is also observed in patients with inflammatory bowel disease, Crohn’s disease, and 
ulcerative colitis, and it is related to disease activity. Vitamin D contributes to the 
integrity of the intestinal barrier and bacterial homeostasis. In addition, vitamin D 
absorption is decreased making supplementation important. Vitamin D deficiency 
is also observed in patients with autoimmune Hashimoto’s thyroiditis. Vitamin D 
deficiency is found in patients with systemic sclerosis, especially the diffuse form 
of the disease. It appears that optimal levels of vitamin D are important for immune 
function and for the prevention of autoimmunity in the human organism.
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